EU MDR CE Marking: Complete Guide for Medical Device Manufacturers

The exact process depends on the device’s intended purpose, classification, technology, and applicable conformity assessment procedure. A typical EU MDR CE Marking pathway includes the following steps.

Step 1: Define the Intended Purpose

The manufacturer should clearly establish the device’s intended purpose, indications, users, target population, operating principle, and claims. The intended purpose is important because it influences classification, clinical evaluation, risk management, labeling, and the overall regulatory strategy.

Step 2: Determine the Medical Device Classification

Under MDR Article 51, medical devices are classified as:

• Class I
• Class IIa
• Class IIb
• Class III

Classification is based on the device’s intended purpose and inherent risks and must be performed according to the rules in MDR Annex VIII.

Manufacturers should carefully evaluate the classification rules because the classification determines the applicable conformity assessment pathway. The European Commission also updated its guidance on medical device classification in April 2026 through MDCG 2021-24 rev.1.

Step 3: Establish the Applicable Conformity Assessment Route

Once the device is classified, the manufacturer determines the applicable conformity assessment procedure.

Depending on the device, this may involve assessment of:

• Quality management system
• Technical documentation
• Product conformity
• Clinical evaluation
• Sterility
• Measuring function
• Specific product characteristics

For Class IIa, IIb and III devices, third-party assessment by an appropriately designated Notified Body is generally required, subject to the specific MDR conformity assessment route and device characteristics.

For certain Class I devices, manufacturers can complete the applicable conformity assessment without Notified Body involvement where the MDR permits self-declaration for example, where the device is not sterile and does not have a measuring function. The MDR’s Article 52 and Annexes IX–XI establish the conformity assessment framework.

Step 4: Implement a Quality Management System

Manufacturers should establish and maintain a quality management system appropriate to their organization and devices.

A QMS typically addresses areas such as:

• Design and development
• Document control
• Supplier management
• Production controls
• Risk management
• CAPA
• Complaint handling
• Change control
• Internal audits
• Post-market surveillance

ISO 13485 is widely used by medical device manufacturers to establish a compliant quality management system, although the regulatory obligations arise from the applicable legislation and conformity assessment requirements.

Step 5: Prepare Technical Documentation

Technical documentation is a central component of EU MDR compliance. MDR Annex II and Annex III establish requirements for technical documentation and post-market surveillance documentation.

Depending on the device, documentation can include:

• Device description and specification
• Intended purpose
• Classification rationale
• Design and manufacturing information
• Risk management documentation
• Verification and validation evidence
• Clinical evaluation
• Labeling and instructions for use
• Software documentation where applicable
• Biocompatibility information
• Sterilization validation where applicable
• Packaging validation
• Usability engineering documentation where applicable
• Post-market surveillance documentation

The documentation should demonstrate that the device meets the applicable General Safety and Performance Requirements (GSPR).

Step 6: Conduct Clinical Evaluation

Clinical evaluation is a significant part of EU MDR compliance. Manufacturers must establish and maintain a clinical evaluation based on relevant clinical data and other appropriate evidence. The MDR places greater emphasis on clinical evidence and ongoing evaluation throughout the device lifecycle.

Depending on the device, the manufacturer may need to consider:

• Clinical data
• Scientific literature
• Clinical investigations
• Post-market clinical follow-up (PMCF)
• Equivalence evidence where applicable

Manufacturers should not assume that older clinical documentation prepared under the MDD will automatically satisfy current MDR requirements.

Step 7: Complete Risk Management

Risk management should be integrated throughout the device lifecycle. Manufacturers typically use ISO 14971 as the framework for medical device risk management. The risk management process should address reasonably foreseeable hazards, risks associated with the intended use, and appropriate risk-control measures.

Risk management should also remain connected to:

• Clinical evaluation
• Design controls
• Labeling
• Usability
• Post-market surveillance
• CAPA
• PMS and PMCF activities

Step 8: Undergo Notified Body Assessment Where Required

Where the applicable conformity assessment procedure requires third-party assessment, the manufacturer works with an MDR-designated Notified Body. A Notified Body is an organization designated to perform conformity assessment activities where third-party intervention is required. The European Commission publishes information about designated Notified Bodies through the NANDO system.

The assessment may include:

• QMS audit
• Technical documentation review
• Device-specific assessment
• Clinical evidence review
• Surveillance audits
• Certificate issuance

The exact assessment depends on the device and selected conformity assessment procedure.

Step 9: Prepare the EU Declaration of Conformity

After completing the applicable conformity assessment process, the manufacturer prepares the EU Declaration of Conformity (DoC). The declaration confirms that the manufacturer assumes responsibility for compliance with the applicable requirements of the MDR. The manufacturer can then affix the CE marking in accordance with the MDR requirements.

Step 10: Complete UDI and EUDAMED Requirements

The MDR introduced a stronger identification and traceability framework through Unique Device Identification (UDI). EUDAMED is the European database for medical devices and supports regulatory transparency, device registration, economic operator information, certificates, and market surveillance.

As of 28 May 2026, the first four EUDAMED modules became mandatory:

1. Actor registration
2. UDI/Devices registration
3. Notified Bodies & Certificates
4. Market Surveillance

Manufacturers entering the EU market should therefore include EUDAMED obligations in their current MDR compliance strategy.

Step 11: Affix the CE Marking

The CE marking should be affixed after the applicable conformity assessment requirements have been completed. Under MDR Article 20, the CE marking must be visible, legible, and indelible. Where it cannot appropriately be placed on the device, the MDR provides for alternative locations such as packaging, and the marking also appears in the instructions for use and sales packaging as applicable. Where a Notified Body has been involved in the conformity assessment, its identification number is placed next to the CE marking where required.

Step 12: Maintain Post-Market Compliance

EU MDR CE Marking is not a one-time activity that ends when the device reaches the market. Manufacturers must maintain compliance throughout the device lifecycle.

Post-market activities may include:

• Post-market surveillance (PMS)
• Vigilance
• Trend reporting
• Complaint handling
• CAPA
• Periodic Safety Update Reports (PSUR), where applicable
• Post-market clinical follow-up (PMCF), where applicable
• Field safety corrective actions
• Regulatory reporting
• Technical documentation updates

The MDR emphasizes a lifecycle approach to safety and includes reinforced post-market monitoring requirements.